Search Results

You are looking at 111 - 120 of 1,029 items for :

  • "community" x
  • Refine by Access: All x
Clear All
Full access

The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos

classified into categories of 18 to 25 and 26 to 30. Cancer centers were divided according to the NCI classification into (1) community centers that treat 100 to 500 newly diagnosed cancer cases annually, (2) comprehensive community centers that treat ≥500

Full access

Primary Palliative Care Improves Uptake of Advance Care Planning Among Patients With Advanced Cancers

Michael G. Cohen, Andrew D. Althouse, Robert M. Arnold, Douglas White, Edward Chu, Margaret Rosenzweig, Kenneth J. Smith, and Yael Schenker

palliative care specialists have expertise in negotiating ACP, access to specialty palliative care is limited, particularly at community cancer centers that are geographically distant from larger academic facilities. 16 The CONNECT study addressed this

Full access

Priorities of Unmet Needs for Those Affected by Colorectal Cancer: Considerations From a Series of Nominal Group Technique Sessions

Sharyn F. Worrall, Andrea J. Dwyer, Reese M. Garcia, Keavy E. McAbee, and Anjelica Q. Davis

, these unmet needs must be identified and prioritized within the CRC population. Although efforts to improve the patient and survivor experience have gained momentum over the past decade, it is essential to ensure that the CRC community has their needs

Full access

Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer

Richard Li, Wei-Hsien Hou, Joseph Chao, Yanghee Woo, Scott Glaser, Arya Amini, Rebecca A. Nelson, and Yi-Jen Chen

(OR, 1.68; 95% CI, 1.43–1.99; P <.001), Charlson-Deyo comorbidity score ≥2 (OR, 1.46; 95% CI, 1.18–1.81; P <.001), treatment at community facility rather than academic (OR, 1.27; 95% CI, 1.07–1.51; P =.006), and T2 disease compared with the

Full access

What Constitutes Quality of Life? Perspectives of Adolescents and Young Adults With Advanced Cancer

Jane Hinkle, Lori Wiener, Andrea Altschuler, Katharine E. Brock, Mallory Casperson, Chun R. Chao, Lauren Fisher, Lawrence H. Kushi, Joshua R. Lakin, Anna Lefebvre, Corey M. Schwartz, Dov M. Shalman, Catherine B. Wall, and Jennifer W. Mack

. Finally, a majority of patient recruitment occurred at academic tertiary care centers whose patient populations may differ from those who seek care at community cancer centers. Further research is required to validate these findings among younger AYAs

Full access

Renal Cell Cancer: A Shift in Approaches for Treatment of Advanced Disease in the United States

Matthew P. Banegas, Linda C. Harlan, Bhupinder Mann, and K. Robin Yabroff

RCC in community practice were examined, focusing on systemic therapy. Patients and Methods Data Source and Study Sample NCI Patterns of Care Data: The NCI SEER program collects information on all cancer diagnoses in defined geographic

Full access

Impact of Nonadherence to NCCN Adjuvant Radiotherapy Initiation Guidelines in Head and Neck Squamous Cell Carcinoma in an Underserved Urban Population

Anusha Ponduri, David Z. Liao, Nicolas F. Schlecht, Gregory Rosenblatt, Michael B. Prystowsky, Rafi Kabarriti, Madhur Garg, Thomas J. Ow, Bradley A. Schiff, Richard V. Smith, and Vikas Mehta

. Methods We identified 184 cases of primary adult HNSCC treated at an urban, community-based academic health center between March 1, 2005, and March 8, 2017. The study protocol was approved by the Institutional Review Board (IRB 2018-9739). Patients with

Full access

Role of Advocates in Research: The Research Advocate Network (RAN) as a Model for Advocate Participation

Judy Perotti, Elda Railey, Mary Lou Smith, and Cheya Pope

Full access

The Quickening Pace of Oncology Research

Rodger J. Winn

Full access

Point/Counterpoint: Early Detection of Prostate Cancer: Do the Benefits Outweigh the Consequences?

Peter R. Carroll and Andrew J. Vickers

Few clinical issues have polarized the oncology community as much as screening for prostate cancer, with advocates of prostate-specific antigen (PSA) testing vocal on one side and skeptics just as vocal on the other. At the NCCN 19th Annual Conference, Dr. Peter R. Carroll and Dr. Andrew J. Vickers tackled the controversy surrounding early detection of prostate cancer, focusing attention on the randomized trial results at the heart of the matter; over-detection (the Achilles’ heel of screening); and the rationale behind the new, streamlined 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection, which emphasize selective early detection and treatment and are tightly aligned with the NCCN Guidelines for Prostate Cancer.